---
title: "DC 7716 - Aplastic anemia:"
diagnostic_code: "7716"
body_system: "Hemic and Lymphatic Systems"
cfr_section: "§ 4.117"
canonical: "https://veteranai.co/va-rating-schedule/hemic-and-lymphatic/7716-aplastic-anemia"
source: "https://www.ecfr.gov/current/title-38/section-4.117"
updated: "2026-07-21T21:09:35.670927Z"
---

# DC 7716 - Aplastic anemia:

Rated under § 4.117. Body system: Hemic and Lymphatic Systems.

## Rating criteria

| Rating | Criteria |
| --- | --- |
| 100% | Requiring peripheral blood or bone marrow stem cell transplant; or requiring transfusion of platelets or red cells, on average, at least once every six weeks per 12-month period; or infections recurring, on average, at least once every six weeks per 12-month period |
| 60% | Requiring transfusion of platelets or red cells, on average, at least once every three months per 12-month period; or infections recurring, on average, at least once every three months per 12-month period; or using continuous therapy with immunosuppressive agent or newer platelet stimulating factors |
| 30% | Requiring transfusion of platelets or red cells, on average, at least once per 12-month period; or infections recurring, on average, at least once per 12-month period |

## Notes

- Note (1): A 100 percent evaluation for peripheral blood or bone marrow stem cell transplant shall be assigned as of the date of hospital admission and shall continue with a mandatory VA examination six months following hospital discharge. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter
- Note (2): The term ânewer platelet stimulating factorsâ includes medication, factors, or other agents approved by the United States Food and Drug Administration

# VA Disability Ratings for Aplastic Anemia (Diagnostic Code 7716)

## Understanding Aplastic Anemia and How the VA Rates It

Aplastic anemia is a condition affecting the **Hemic and Lymphatic Systems**. The VA evaluates it under **Diagnostic Code 7716**, found in **§ 4.117** of the rating schedule.

The VA assigns a disability rating based on how the condition is being treated and managed — including whether you require transfusions, experience recurring infections, need ongoing medication, or have undergone a stem cell transplant. The more frequent and intensive the required care, the higher the rating level.

---

## Available Rating Levels

### 100% Rating
Assigned when the condition is:
- Requiring peripheral blood or bone marrow stem cell transplant; **or**
- Requiring transfusion of platelets or red cells, on average, at least once every six weeks per 12-month period; **or**
- Infections recurring, on average, at least once every six weeks per 12-month period.

### 60% Rating
Assigned when the condition is:
- Requiring transfusion of platelets or red cells, on average, at least once every three months per 12-month period; **or**
- Infections recurring, on average, at least once every three months per 12-month period; **or**
- Using continuous therapy with an immunosuppressive agent or newer platelet stimulating factors.

### 30% Rating
Assigned when the condition is:
- Requiring transfusion of platelets or red cells, on average, at least once per 12-month period; **or**
- Infections recurring, on average, at least once per 12-month period.

---

## What the VA Looks For

When rating aplastic anemia, the VA focuses on the type and frequency of treatment your condition requires over a 12-month period. Key factors include:

- **Transfusions** — how often you require transfusion of platelets or red cells, measured on average across a 12-month period.
- **Recurring infections** — how frequently infections recur, measured on average across a 12-month period.
- **Ongoing therapy** — whether you use continuous therapy with an immunosuppressive agent or newer platelet stimulating factors.
- **Stem cell transplant** — whether you require a peripheral blood or bone marrow stem cell transplant.

---

## Important Notes

**Note (1):** A 100 percent evaluation for peripheral blood or bone marrow stem cell transplant is assigned as of the date of hospital admission and continues with a mandatory VA examination six months following hospital discharge. Any change in evaluation based upon that or any subsequent examination is subject to the provisions of § 3.105(e).

**Note (2):** The term "newer platelet stimulating factors" includes medication, factors, or other agents approved by the United States Food and Drug Administration.

Source: https://www.ecfr.gov/current/title-38/section-4.117